Highlights of BioNTech’s oncology programs to be presented at AACR 2025: ...

Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers ...

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

In PD-(L)1 resistant hot tumors, solnerstotug+cemiplimab showed 14% ORR, nearly 3x higher than historical PD-(L)1 rechallenge response rates Solnerstotug remains well tolerated, with no dose ...